Urinary CBD Metabolite Abundance and Persistence Described Different Features
The most abundant urinary CBD metabolite was not the one with the longest reported terminal half-life. Amount and persistence should remain separate when interpreting the study’s excretion profiles.
The investigators measured several analytes
Across the study conditions, the reported urinary abundance order was 7-hydroxy-CBD, then CBD, then 7-carboxy-CBD. The carboxy metabolite nevertheless had the longest reported terminal half-life, approximately thirty hours across inhaled routes and fifty-two hours across oral formulations. These were urinary pharmacokinetic summaries after single-dose conditions.
A longer tail does not require the largest peak
Peak concentration, total excretion and a terminal decline parameter characterize different parts of an analyte’s profile. The apparent mismatch is therefore not a contradiction. It would be misleading to call the most abundant compound the longest-lasting without examining which metric the statement uses. These urine findings also should not be relabeled as plasma or brain measurements.
No universal detection deadline follows
A terminal half-life does not specify exactly when every laboratory will stop detecting the compound. Sampling, assay sensitivity, individual variation and repeated dosing affect that question. The study’s small formulation groups and interval-based urine collection further qualify precision. Its results support analyte-specific interpretation rather than a single duration assigned to all CBD-related urine signals.
Related analysis: the urinary CBD route comparison.
Research cited
Sholler and colleagues (2021). Urinary Pharmacokinetic Profile of Cannabidiol, THC and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. DOI: 10.1093/jat/bkab059.
